Limits...
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB - Oncotarget (2015)

Bottom Line: Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively.Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH.No obvious side effects of Rapatar were detected.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.

ABSTRACT
Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

No MeSH data available.


Related in: MedlinePlus

Effect of Rapatar on body weightS-BPH: Sulpiride-induced BPH (Groups #7– 12). Body weight was measured twice a week.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496392&req=5

Figure 6: Effect of Rapatar on body weightS-BPH: Sulpiride-induced BPH (Groups #7– 12). Body weight was measured twice a week.

Mentions: During the experiment, rats gained significant weight. This weight gain is explained by housing of each rat in individual cage that reduces stress and is commonly associated with weight gain. The same weight gain was observed in control BPH groups and in BPH groups treated with Finasteride (Figure 6). In S-BPH, Rapatar partially prevented weight gain. This effect was dose dependent (Figure 6). At doses 1.5 mg/kg and 3 mg/kg, Rapatar decreased weight by 13% and 17, respectively (Figure 6). It was previously reported that rapamycin decreased obesity in rodents on high-fat diet [20-23].


Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB - Oncotarget (2015)

Effect of Rapatar on body weightS-BPH: Sulpiride-induced BPH (Groups #7– 12). Body weight was measured twice a week.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496392&req=5

Figure 6: Effect of Rapatar on body weightS-BPH: Sulpiride-induced BPH (Groups #7– 12). Body weight was measured twice a week.
Mentions: During the experiment, rats gained significant weight. This weight gain is explained by housing of each rat in individual cage that reduces stress and is commonly associated with weight gain. The same weight gain was observed in control BPH groups and in BPH groups treated with Finasteride (Figure 6). In S-BPH, Rapatar partially prevented weight gain. This effect was dose dependent (Figure 6). At doses 1.5 mg/kg and 3 mg/kg, Rapatar decreased weight by 13% and 17, respectively (Figure 6). It was previously reported that rapamycin decreased obesity in rodents on high-fat diet [20-23].

Bottom Line: Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively.Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH.No obvious side effects of Rapatar were detected.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.

ABSTRACT
Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

No MeSH data available.


Related in: MedlinePlus